Cancer Therapy

Pharma company provides clinical trial update

Published in Gene Therapy Weekly, October 28th, 2004

Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) presented interim phase I clinical data for M200, its antialpha5beta1 integrin antibody for the treatment of refractory solid tumors, at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.

The data were reported in a poster presentation by Dr. Eric Rowinsky, clinical professor of Medicine, University of Texas Health Science Center and senior scientist, CTRC Institute for Drug Development, San Antonio, Texas.

This ongoing study is a phase I dose-escalation clinical trial. Sixteen men and women between the ages of 29 and 81 (mean 58 years) with various...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-10-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry